Skip to main content
Explore URMC

menu

Brain Cancer: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Research Question:
Is temozolomide more effective in treating glioblastoma multiforme with or without the addition of veliparib?

Basic Study Information

Purpose:
This randomized phase II/III trial studies how well temozolomide and veliparib work and compare them to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.

Location: Cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02152982?term=A+Phase+II%2FIII+Randomized+Trial+of+Veliparib+or+Placebo+in+Combination+With+Adjuvant+Temozolomide+in+Newly+Diagnosed+Glioblastoma+With+MGMT+Promoter+Hypermethylation&rank=1
Study Reference #: CBRT-15027

Lead Researcher (Principal Investigator)

Lead Researcher: Nimish Mohile

Study Contact Information

Study Coordinator: Jennifer Serventi
Phone: (585) 276-3971
Email: Jennifer_Serventi@urmc.rochester.edu

Additional Study Details

Return to Search